title: [Radiofrequency ablation of malignant lung tumors--preliminary report of 12 cases].
abstract: Percutaneous CT fluoroscopy-guided radiofrequency ablation (RFA) was performed in 12 patients with 4 primary and 8 metastatic lung cancers as a pilot study. The main complication was a pneumothorax, which occurred in six cases and 2 of them required a chest tube drainage. Four patients died of extrapulmonary tumor progression at 3-17 months after RFA. The remaining 8 patients were alive with the disease and their median follow-up period was 12 months (range, 6-39 months). An overall survival rate was 75% at 6 months, 63% at 1 year and 43% at 2 years. A local progression occurred in 4 cases at 4-17 months after RFA and the cause of relapse was considered as insufficient ablation due to tumor localization close to the trachea, SVC or intrapulmonary vessels and bronchi. A local control rate was 92% at 6 months, 64% at 1 year and 35% at 2 years.
  
  
  CONCLUSIONS
  RFA of lung tumors is a safe and minimally invasive therapeutic intervention with a good local control for sufficiently ablated lesions. So it appears to be a favorable treatment option for high-risk patients or those with multiple lesions.
authors.affiliation: Dept. of Surgery, Suita Municipal Hospital.
authors.forename: Hideoki
authors.initials: H
authors.lastname: Yokouchi
authors.forename: Taku
authors.initials: T
authors.lastname: Yasumoto
authors.forename: Kohei
authors.initials: K
authors.lastname: Murata
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Tomimaru
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Ide
authors.forename: Hiroki
authors.initials: H
authors.lastname: Matsunaga
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Okada
authors.forename: Hideo
authors.initials: H
authors.lastname: Ota
authors.forename: Kentaro
authors.initials: K
authors.lastname: Maruyama
authors.forename: Toshikatsu
authors.initials: T
authors.lastname: Kinuta
mesh_terms: D000368:Aged; D017115:Catheter Ablation / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D014057:Tomography, X-Ray Computed